Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease.
Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.
Large-scale study found that long COVID patients exhibit sustained inflammation and specific immune responses associated with varying symptoms, highlighting the importance of personalized treatment approaches.